Kymera Therapeutics announced the clearance of its Investigational New Drug, IND, application from the U.S. Food and Drug Administration, FDA, for KT-621, a potent, selective, oral degrader of STAT6. The Company expects to initiate dosing in a Phase 1 clinical trial in healthy volunteers in October 2024 and to report data from the Phase 1 study in the first half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $56 from $52 at Oppenheimer
- Kymera Therapeutics presents data for KT-621 at EADV Congress
- Kymera assumed with Outperform from Market Perform at Leerink
- Boeing’s Starliner to return without astronauts: Morning Buzz
- Kymera upgraded, MoonLake downgraded: Wall Street’s top analyst calls